Portfolio News
- July 19, 2012 - Dow Jones VentureWirePharmaceutical Developer Durata Trades Up 8.1% Post-IPO
- July 18, 2012 - Dow Jones VentureWireSofinnova Ventures, NEA Join $40M PIPE For Alimera Sciences
- July 02, 2012 Amarin Announces Notice of Allowance for Additional U.S. Patent Covering AMR101
- July 02, 2012 Tesaro’s 30% solution
- June 28, 2012 Tesaro Completes $81M IPO; New Investor Sofinnova Joins Insiders in Offering
- June 22, 2012 Volubill Named as a Leading Convergent Charging Software Provider by Infonetics Research
- May 29, 2012 Amarin Announces U.S. Patent Issuance for AMR101
- May 29, 2012 Cortina’s PON Innovation Accelerates Adoption in Fast Growing 10G EPON and EPON/GPON Markets
- May 24, 2012 Data for Amarin's AMR101 to be Presented at the National Lipid Association 2012 Annual Scientific Sessions
- May 22, 2012 Sorbent Therapeutics’ CLP1001 Improves Heart Failure Symptoms
In Phase 2 Clinical Study
- May 18, 2012 Ocera Therapeutics receives CE Mark for Zysa(TM) for the treatment of diarrhea-predominant Irritable Bowel Syndrome (IBS-d)
- April 30, 2012 CrestaTech Secures $13M to Develop Smart Tuners for TV and Mobile Devices
- April 13, 2012 Hyperion Therapeutics Files Registration Statement for Proposed Initial Public Offering
- April 13, 2012 Guavus Sees Analytics As Key To Big Data
- March 22, 2012 Durata Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
< More recent articles | Past articles >
Events
- October 28, 2013Mike Powell, BioNetwork West 2013 - "The Outlook for Traditional Venture Capital Firms: Evolving Trends and Opportunities"
- October 22, 2013Sofinnova Japan BioPharma Partnering Conference
- June 18, 2013Jennifer James, 2013 PEI Investor Relations Forum "Fundraising the next generation"
- March 25, 2013Mike Powell, Lecture at UCSF - "Lessons Learned in Venture Capital: What I learned the Hard Way, the Easy Way, and from the Entrepreneurs"
- February 12, 2013Anand Mehra Presents to Bio2Device Group
Media Contact
Jennifer James
VP of Marketing and Investor Relations
Sofinnova Ventures
jennifer@sofinnova.com
(650) 681-8429
